Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellectis bioresearch, a commercial subsidiary of Cellectis, has won indefinite delivery/indefinite quantity (IDIQ) contract to provide services to the National Institutes of Health (NIH) and certain other government agencies.
Subscribe to our email newsletter
The five-year contract with a maximum order limit of $9,509,000 possibly includes production of clinical grade induced pluripotent stem (iPS) cell lines and differentiation of iPS cells in the direction of specific tissue cell type of clinical grade.
Cellectis bioresearch CEO Marc Le Bozec said, "This contract won through a NIH call for tenders is the largest ever secured by Cellectis bioresearch Inc."
Cellectis CEO Andre Choulika said, "This contract award granted by the most prestigious US research organization the NIH is a great recognition of our Science and confirms that Cellectis is one of the major players at developing Stem cell technologies in both in vitro research applications and regenerative medicine."